All In Biotech

Drug Trial Radar · NCT04579588

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Oct 29, 2020

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Conditions

  • Corona Virus Infection
  • Flu Vaccine
  • Immunity

Interventions

  • Flu shotBiological

    All participants will receive a single shot of the flu vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Testing immunity to the flu vaccine over timeTime frame: 1 week
  2. Testing immunity to the flu vaccine over timeTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.